Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBITDA (2022 - 2025)

CervoMed (CRVO) has disclosed EBITDA for 9 consecutive years, with -$8.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 19.41% to -$8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.0 million through Dec 2025, down 66.42% year-over-year, with the annual reading at -$27.0 million for FY2025, 66.42% down from the prior year.
  • EBITDA hit -$8.1 million in Q4 2025 for CervoMed, down from -$7.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $2.2 million in Q3 2023 to a low of -$8.1 million in Q4 2025.
  • Historically, EBITDA has averaged -$4.0 million across 4 years, with a median of -$4.1 million in 2022.
  • Biggest five-year swings in EBITDA: skyrocketed 176.83% in 2023 and later plummeted 314.41% in 2024.
  • Year by year, EBITDA stood at -$4.0 million in 2022, then surged by 41.3% to -$2.4 million in 2023, then tumbled by 186.7% to -$6.8 million in 2024, then fell by 19.41% to -$8.1 million in 2025.
  • Business Quant data shows EBITDA for CRVO at -$8.1 million in Q4 2025, -$7.7 million in Q3 2025, and -$6.3 million in Q2 2025.